科研之友
微信
新浪微博
Facebook
分享链接
摘要
Aim: To observe the effects of hydrochloride pioglitazone on monocyte chemoattractant protein-1 (MCP-1) excretion in type 2 diabetics and explore its reno-protective mechanism. Methods: 98 uncontrolled type 2 diabetics with fasting blood glucose (FBG) between 7.0 and 13.0 mmol/L and glycated hemoglobin A1c (HbA1c) >= 7.0% were assigned randomly into group DP (pioglitazone add-on) and group DS (sulfonylureas add-on). Another 49 healthy individuals were chosen as normal controls (group NC). At the basal and 12th week, FBG, HbA1c, urinary MCP-1, albumin (UALB) and creatinine (UCr) were determined. Results: (1) Compared with group NC, all the parameters mentioned above were significantly increased in diabetic groups. (2) Compared with pre-treatment, FBG, HbA1c and urinary MCP-1/UCr ratio (UMCR) were obviously decreased in both therapy groups; systolic blood pressure (SBP), diastolic blood pressure (DBP) and UALB/UCr ratio (UACR) decreased markedly in group DP (P < 0.05 or P < 0.01), while slightly in group DS (P > 0.05). (3) FBG and HbA1c had no marked difference between group DP and group DS after treatment, however, SBP, DBP, UACR and UMCR in group DP were significantly lower than those in group DS (P < 0.05 or P < 0.01). Conclusions: Pioglitazone can decrease urinary albumin and MCP-1 excretion in type 2 diabetics, which may partly contribute to its reno-protection by inhibiting the inflammation reaction in vivo.
